Augtyro (Repotrectinib) Patent Expiration, LOE Window & CMS Spending

Augtyro (Repotrectinib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2036-07-05 (last listed 2036-07-24), 0 AB generics, $13.3M 2024 CMS Part D & Medicaid spend, and $30,740 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN218213 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-07-05
Last Listed Patent or Exclusivity Date2036-07-24
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$13.3M
2024 Medicare Part D Spend$9.8M
2024 Medicaid Spend$3.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($30,740 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.